News provided by Eli Lilly and Company May 21, 2026, 06:45 ET In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI 35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs
For a specific comparison of these medications, see our Mounjaro vs Ozempic and Zepbound vs Wegovy guides
Regulatory restrictions may apply
However, this effect isn't directly through GCG receptor but through another protein called FGF21, which is secreted by the liver
Scientific Data: A study found that Byetta was associated with more frequent nausea compared to other GLP-1 medications